E

Lessons learned from phase 1 oncology trials

A novel IO target with a chequered history is starting to look more promising - which one and why?

January 21, 2021
E

Strategic direction and future impacts in multiple myeloma

A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?

January 14, 2021
E

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021
E

Looking through the window at the cilta-cel data

A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed

January 12, 2021
E

An exciting pipeline of early stage oncology agents from BMS

A critical look at the early stage BMS oncology pipeline

January 11, 2021
E

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021
E

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021
E

If it’s Tuesday it must be Belgium

It's time to turn our attention to novel TKI approaches in hematologic malignancies

December 8, 2020
E

A critical review of bispecific antibodies at ASH20

What caught our attention on novel bispecific antibodies at ASH20?

December 7, 2020
E

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020
E

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020
E

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020
E

ASH20 Preview – Part 1 on small molecule developments

New developments in the BTK niche offer fresh insights on progress

December 1, 2020
E

ASH20 CAR-T cell therapy Preview

Rock around the CAR-T cell clock to learn what to watch out for at ASH20!

November 24, 2020
E

ASH20 Preview 2 on Antibodies and ADCs

What's hot on the antibody and ADC front at ASH 2020?

November 12, 2020
E

ASH20 Preview of progress with bispecific antibodies

Updated look at the bispecific landscape in early clinical development

November 9, 2020